276 related articles for article (PubMed ID: 33611678)
1. Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients.
Tesch ME; Chia SK; Simmons CE; LeVasseur N
Breast Cancer Res Treat; 2021 May; 187(1):167-176. PubMed ID: 33611678
[TBL] [Abstract][Full Text] [Related]
2. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Chemotherapy of Taxanes With or Without Anthracyclines in Different Molecular Subtypes of Breast Cancer: A Propensity Score Matching Study.
Xiao J; Wang T; Yi J; Huang M; Yan C; Ling R
Clin Breast Cancer; 2023 Dec; 23(8):882-893. PubMed ID: 37833133
[TBL] [Abstract][Full Text] [Related]
4. [Response and prognosis of neoadjuvant dose-dense or standard schedule chemotherapy with anthracyclines and taxanes for Luminal B breast cancer].
Qiu AF; Miao ZL; Ge GK; Wang CB; Bian J; Ma HY; Xu Q
Zhonghua Yi Xue Za Zhi; 2017 Nov; 97(44):3466-3470. PubMed ID: 29275580
[No Abstract] [Full Text] [Related]
5. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
González-Santiago S; Saura C; Ciruelos E; Alonso JL; de la Morena P; Santisteban Eslava M; Gallegos Sancho MI; de Luna A; Dalmau E; Servitja S; Ruiz Borrego M; Chacón JI
Breast Cancer Res Treat; 2020 Nov; 184(2):469-479. PubMed ID: 32876911
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
[TBL] [Abstract][Full Text] [Related]
7. Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials.
Bria E; Carbognin L; Furlanetto J; Pilotto S; Bonomi M; Guarneri V; Vicentini C; Brunelli M; Nortilli R; Pellini F; Sperduti I; Giannarelli D; Pollini GP; Conte P; Tortora G
Cancer Treat Rev; 2014 Aug; 40(7):847-56. PubMed ID: 24877987
[TBL] [Abstract][Full Text] [Related]
8. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes.
Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G
Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508
[TBL] [Abstract][Full Text] [Related]
9. Locoregional Recurrence and Survival Outcomes in Breast Cancer Treated With Modern Neoadjuvant Chemotherapy: A Contemporary Population-based Analysis.
Murchison S; Nichol A; Speers C; Gondara L; Levasseur N; Lohrisch C; Vallieres I; Truong P
Clin Breast Cancer; 2022 Oct; 22(7):e773-e787. PubMed ID: 35915021
[TBL] [Abstract][Full Text] [Related]
10. Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer.
Ma X; Zhang X; Zhou X; Ren X; Ma X; Zhang W; Yang R; Song T; Liu Y
Medicine (Baltimore); 2022 Oct; 101(40):e30892. PubMed ID: 36221359
[TBL] [Abstract][Full Text] [Related]
11. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
[TBL] [Abstract][Full Text] [Related]
13. Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers.
Ortmann O; Blohmer JU; Sibert NT; Brucker S; Janni W; Wöckel A; Scharl A; Dieng S; Ferencz J; Inwald EC; Wesselmann S; Kowalski C;
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1195-1209. PubMed ID: 35380257
[TBL] [Abstract][Full Text] [Related]
14. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
de Moura Leite L; Cesca MG; Tavares MC; Santana DM; Saldanha EF; Guimarães PT; Sá DDS; Simões MFE; Viana RL; Rocha FG; Loose SK; Silva SF; Pirolli R; Fogassa CAZ; Mattos BRS; Campos FAB; Sanches SM; de Lima VCC; Pondé NF
Breast Cancer Res Treat; 2021 Nov; 190(1):155-163. PubMed ID: 34409551
[TBL] [Abstract][Full Text] [Related]
15. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
Clavarezza M; Puntoni M; Gennari A; Paleari L; Provinciali N; D'Amico M; DeCensi A
Clin Cancer Res; 2016 Sep; 22(18):4594-603. PubMed ID: 27140927
[TBL] [Abstract][Full Text] [Related]
16. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
17. Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Wu J; Li S; Jia W; Su F
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1505-10. PubMed ID: 21830158
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer.
De Iuliis F; Salerno G; Corvino R; D'Aniello D; Cefalì K; Taglieri L; Lanza R; Scarpa S
Clin Breast Cancer; 2017 Feb; 17(1):34-40. PubMed ID: 27435626
[TBL] [Abstract][Full Text] [Related]
19. A pharmacophore-based classification better predicts the outcomes of HER2-negative breast cancer patients receiving the anthracycline- and/or taxane-based neoadjuvant chemotherapy.
Li X; Sun H; Liu Q; Liu Y; Hou Y; Jin W
Cancer Med; 2021 Jul; 10(13):4658-4674. PubMed ID: 34076352
[TBL] [Abstract][Full Text] [Related]
20. Effect of time to breast cancer surgery after neoadjuvant chemotherapy on survival outcomes.
Al-Masri M; Aljalabneh B; Al-Najjar H; Al-Shamaileh T
Breast Cancer Res Treat; 2021 Feb; 186(1):7-13. PubMed ID: 33475879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
